🔎 Trials Near Me

Home › Kanser sa Atay (Hepatocellular Carcinoma) › Illinois

Pag-aaral pangklinika para sa Kanser sa Atay (Hepatocellular Carcinoma) sa Illinois

20 pag-aaral para sa Kanser sa Atay (Hepatocellular Carcinoma) ang naghahanap ng mga kalahok sa mga site sa Illinois.

Mga Lungsod sa Illinois

Opisyal na teksto ng pag-aaral (English)

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

  • Exelixis Clinical Site #26, Chicago
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT05176483

Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.

  • Memorial Hospital, Shiloh
  • Siteman Cancer Center - Shiloh, Shiloh
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT07227012

National Liver Cancer Screening Trial

  • Northwestern University, Chicago
Nagre-recruitPhase 4
Edad 18 hanggang 85 · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06084234

Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure

  • OSF St. Francis Medical Center, Peoria
Nagre-recruitPhase 2
Edad 18 hanggang 100 · Lahat ng kasarian · Na-update Set 23, 2026 · NCT07219459

A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

  • Local Institution - 0107, Chicago
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 23, 2026 · NCT07291076

A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

  • City of Hope Chicago Cancer Center, Zion
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 16, 2026 · NCT06427941

Defining the Ablative Dose for Y-90 TARE

  • Northwestern University, Chicago
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 15, 2026 · NCT07586046

Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)

  • RUSH University Medical Center, Chicago
  • University of Chicago, Chicago
Nagre-recruitObservasyonal na pag-aaral
Edad 22 pataas · Lahat ng kasarian · Na-update Set 11, 2026 · NCT06486454

Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

  • Research Site, Chicago
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 3, 2026 · NCT06921785

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

  • Lurie Children's Hospital-Chicago, Chicago
Nagre-recruitPhase 1/2
12 Months – 30 Years · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT04851119

Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial

  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
  • Carle at The Riverfront, Danville
  • at 6 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 17, 2026 · NCT07166406

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

  • Orchard Healthcare Research Inc, Skokie
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 5, 2026 · NCT06330064

Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

  • University of Chicago Comprehensive Cancer Center, Chicago
  • Carle Cancer Center NCI Community Oncology Research Program, Urbana
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 4, 2026 · NCT05168163

DRAGON Registry - International Multicenter Registry and Medical Image Bank for Patients With Primarily Unresectable Liver Cancer or Liver Metastases That Underwent Combined Portal and Hepatic Vein Embolization (PVE/HVE) to Increase Future Liver Remnant Before Resection.

  • Rush University Medical Center, Chicago
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 21, 2026 · NCT07717437

Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer

  • Northwestern University, Chicago
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 25, 2026 · NCT07042919

A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma

  • Clinical Trial Site, Chicago
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 17, 2026 · NCT06600321

Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk

  • Northwestern University, Chicago
  • Northwestern Medicine Kishwaukee Hospital, DeKalb
  • Northwestern Medicine Delnor Hospital, Geneva
  • at 4 pa
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update May 26, 2026 · NCT05620771

Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years

  • University of Chicago Medical Center, Chicago
  • Methodist Medical Center of Illinois, Peoria
Nagre-recruitPhase 4
Edad 18 hanggang 64 · Lahat ng kasarian · Na-update Ene 22, 2026 · NCT04373564

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Chicago
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Okt 28, 2025 · NCT03452774

The Dragon PLC Trial (DRAGON-PLC)

  • Rush University Medical Center, Chicago
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update May 15, 2025 · NCT06914648

Mula sa ClinicalTrials.gov, na-kuha noong Okt 7, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.